NCT06217783 Ultrasound-guided Peripheral Intravenous Catheter Placement in an Oncologic Emergency Department - a Prospective, Randomized Controlled Trial of Catheter Lengths
| NCT ID | NCT06217783 |
| Status | Recruiting |
| Phase | — |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | Oncologic Complications and Emergencies |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2024-03-27 |
| Primary Completion | 2027-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2024-03-27 with a primary completion date of 2027-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To learn about the effects of the length of the catheter on the failure and success rate of USIV placement.
Eligibility Criteria
Inclusion Criteria: 1. Age \> 18 years old. 2. Provision of signed and dated informed consent form. 3. Predetermined to have difficult IV access necessitating USIV placement 4. Expected admission to hospital with anticipated stay \> 48 hours (per discussion with treating physician). Exclusion Criteria: 1. Expected/anticipated discharge disposition from the ACCC (per discussion with treating physician). 2. Inability to give informed consent. 3. Pregnant women. 4. Non-English speaking participants.
Contact & Investigator
Jonathan Rowland, MD
PRINCIPAL INVESTIGATOR
M.D. Anderson Cancer Center
Frequently Asked Questions
Who can join the NCT06217783 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Oncologic Complications and Emergencies. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06217783 currently recruiting?
Yes, NCT06217783 is actively recruiting participants. Contact the research team at jwrowland@mdanderson.org for enrollment information.
Where is the NCT06217783 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT06217783 clinical trial?
NCT06217783 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Jonathan Rowland, MD at M.D. Anderson Cancer Center. The trial plans to enroll 400 participants.